HORSHAM, P.A. (December 17, 2025) Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), th… [+39491 chars]
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib) - Johnson & Johnson
RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions1-5 Approval builds on previously reported Phase 3 MAR…
Source:Jnj.com
Published:
Related News
business
business
business
Gold Surges Above $5,000 on Shutdown Fears, Geopolitical Tensions - WSJ - The Wall Street Journal
The Wall Street Journal•The Wall Street Journal
Stock futures are little changed as traders get set for a big week of trading: Live updates - CNBC
Stock futures were relatively unchanged on Monday as traders braced for a big week, with key earnings reports and a U.S. monetary policy meeting.
CNBC•Sean Conlon, Fred Imbert
Winter storm live updates: Heavy snow blasts Northeast as U.S. battles impacts of 'catastrophic' ice accumulation - Yahoo
'An Arctic siege has taken over our state,' New York governor Kathy Hochul said. 'It is brutal, it is bone-chilling and it is dangerous'
Yahoo Entertainment•Yahoo News Staff